Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Medicus Pharma Ltd.

MDCXNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 17, 2026Accepted Nov 17, 2026, 5:02 PM ESTFiling CIK 1997296Accession 0000950142-26-003103
Share

Structured filing — 4

es260854075_4-bokhari.xml

Open full document ↗

Filing details

Report period
2026-11-13
Issuer
Medicus Pharma Ltd.
Issuer CIK
0001997296
Trading symbol
MDCX

Reporting owner 1

Name
Bokhari Raza
Reporting owner CIK
0001660525
Relationship
Director · Officer · 10% owner
Officer title
Chief Executive Officer
Address
300 CONSHOHOCKEN STATE ROAD, SUITE 200, W. CONSHOHOCKEN, PA, 19428

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnershipNature of ownership
Common Shares, no par value2026-11-13A · Form 4[F1]436,046A1.72451,909ISee Footnote[F2]
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
I
Indirect

Footnotes

F1
On November 13, 2026, RBx Capital, LP, an entity controlled by Dr. Raza Bokhari, entered into a subscription agreement with the Issuer, pursuant to which RBx Capital, LP agreed to purchase 436,046 common shares, no par value, at a purchase price of $1.72 per share in a private placement in which other investors also participated under separate subscription agreements.↩ 1
F2
Held by RBx Capital, LP, an entity controlled by Dr. Raza Bokhari. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.↩ 1

Signature 1

Signed
/s/ Raza Bokhari
Date
2026-11-17

Company context

We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and  accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are  developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").

Current securities

Recent company filings

  1. SCHEDULE 13D/A - filed by Bokhari Raza regarding Medicus Pharma Ltd.Nov 17, 2026
  2. 4 filingNov 17, 2026
  3. 4 filingNov 17, 2026
  4. 424B3 filingNov 16, 2026
  5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Other EventsNov 16, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.